Stephen Johnston

17.0k total citations · 5 hit papers
236 papers, 9.3k citations indexed

About

Stephen Johnston is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Stephen Johnston has authored 236 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 172 papers in Oncology, 134 papers in Pulmonary and Respiratory Medicine and 71 papers in Cancer Research. Recurrent topics in Stephen Johnston's work include Advanced Breast Cancer Therapies (107 papers), HER2/EGFR in Cancer Research (102 papers) and Estrogen and related hormone effects (55 papers). Stephen Johnston is often cited by papers focused on Advanced Breast Cancer Therapies (107 papers), HER2/EGFR in Cancer Research (102 papers) and Estrogen and related hormone effects (55 papers). Stephen Johnston collaborates with scholars based in United Kingdom, United States and Germany. Stephen Johnston's co-authors include Mitch Dowsett, Lesley‐Ann Martin, Ian E. Smith, Simone Detre, Alexandra Léary, Lisa O’Rourke, J. Maltzman, Xavier Pivot, Allison Florance and Masakazu Toi and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Stephen Johnston

227 papers receiving 9.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

2009 766 citations Stephen Johnston, Michael F. Press et al. Journal of Clinical Oncology profile →
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

2019 590 citations Masakazu Toi, Patrick Neven et al. profile →
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

2016 507 citations Charlotte Fribbens, Lucy Kilburn et al. Journal of Clinical Oncology profile →
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

2016 446 citations Hope S. Rugo, Stephen Johnston et al. Journal of Clinical Oncology profile →
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

2019 407 citations Stephen Johnston, Miguel Martín et al. npj Breast Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen Johnston United Kingdom	48	6.3k	4.3k	3.1k	2.5k	2.0k	236	9.3k
Antonio Llombart‐Cussac Spain	43	6.8k 1.1×	3.9k 0.9×	3.5k 1.1×	1.4k 0.5×	1.6k 0.8×	317	9.4k
Angelo Di Leo Italy	62	9.9k 1.6×	4.5k 1.1×	5.2k 1.7×	4.1k 1.6×	1.2k 0.6×	313	14.4k
Sabine C. Linn Netherlands	48	4.7k 0.7×	2.4k 0.6×	3.4k 1.1×	3.2k 1.3×	1.5k 0.8×	231	9.1k
Sara A. Hurvitz United States	53	8.2k 1.3×	4.2k 1.0×	2.6k 0.8×	3.2k 1.3×	1.1k 0.6×	375	11.0k
Sarat Chandarlapaty United States	51	6.0k 0.9×	4.1k 1.0×	2.9k 0.9×	6.3k 2.5×	1.5k 0.8×	205	12.6k
Binghe Xu China	41	6.1k 1.0×	2.8k 0.6×	3.0k 0.9×	3.2k 1.3×	1.2k 0.6×	387	9.1k
Joyce O’Shaughnessy United States	40	7.0k 1.1×	2.8k 0.7×	3.1k 1.0×	2.1k 0.8×	676 0.3×	240	9.6k
Jean-Marc Ferrero France	41	6.4k 1.0×	4.0k 0.9×	3.0k 1.0×	1.8k 0.7×	561 0.3×	207	9.6k
Sara M. Tolaney United States	54	11.6k 1.8×	5.3k 1.2×	3.7k 1.2×	2.8k 1.1×	756 0.4×	502	14.8k
Aleix Prat Spain	55	8.9k 1.4×	3.5k 0.8×	6.1k 2.0×	5.8k 2.3×	1.2k 0.6×	395	14.7k

Countries citing papers authored by Stephen Johnston

Since Specialization

Citations

This map shows the geographic impact of Stephen Johnston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Johnston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Johnston more than expected).

Fields of papers citing papers by Stephen Johnston

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Johnston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Johnston. The network helps show where Stephen Johnston may publish in the future.

Co-authorship network of co-authors of Stephen Johnston

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Johnston. A scholar is included among the top collaborators of Stephen Johnston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Johnston. Stephen Johnston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Loi, Sherene, Stephen Johnston, Carlos L. Arteaga, et al.. (2024). Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).. Journal of Clinical Oncology. 42(17_suppl). LBA507–LBA507. 12 indexed citations

Cutts, Ros, Sarah Hrebien, Aditi Gulati, et al.. (2024). Discriminating subtypes in advanced breast cancer with ctDNA methylation profiling.. Journal of Clinical Oncology. 42(16_suppl). 1013–1013.

Hamilton, Erika, Timothy Pluard, Judy S. Wang, et al.. (2024). H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).. Journal of Clinical Oncology. 42(16_suppl). 1015–1015. 4 indexed citations

Goetz, Matthew P., İrfan Çiçin, Laura Testa, et al.. (2024). Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. npj Breast Cancer. 10(1). 34–34. 12 indexed citations

O’Shaughnessy, Joyce, Laura Testa, Sara M. Tolaney, et al.. (2023). 274P Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study. Annals of Oncology. 34. S293–S293. 1 indexed citations

Harbeck, Nadia, Priya Rastogi, J. O’Shaughnessy, et al.. (2023). LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. Annals of Oncology. 34. S1256–S1256. 11 indexed citations

Turner, Nicholas C., Hironobu Sasano, Carlos L. Arteaga, et al.. (2023). 240MO Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: An exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC). Annals of Oncology. 34. S278–S279. 2 indexed citations

Pancholi, Sunil, Nikiana Simigdala, Ricardo Ribas, et al.. (2022). Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer. npj Breast Cancer. 8(1). 125–125. 10 indexed citations

Johnston, Stephen, Joyce O’Shaughnessy, Miguel Martín, et al.. (2021). Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. npj Breast Cancer. 7(1). 80–80. 36 indexed citations

10.

Turner, Nicholas C., Claire Swift, Lucy Kilburn, et al.. (2020). ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials. Clinical Cancer Research. 26(19). 5172–5177. 100 indexed citations

11.

Pancholi, Sunil, Ricardo Ribas, Nikiana Simigdala, et al.. (2020). Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities. Oncogene. 39(25). 4781–4797. 63 indexed citations

12.

Prat, Aleix, Yi‐Hsuan Tsai, Tomás Pascual, et al.. (2020). A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer. Clinical Cancer Research. 26(23). 6141–6148. 5 indexed citations

13.

Ribas, Ricardo, Sunil Pancholi, Stephanie K. Guest, et al.. (2015). AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo. Molecular Cancer Therapeutics. 14(9). 2035–2048. 49 indexed citations

14.

Finn, Richard S., Michael F. Press, Judy Dering, et al.. (2013). Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer. Clinical Cancer Research. 20(3). 736–743. 20 indexed citations

15.

Léary, Alexandra, Suzanne Drury, Simone Detre, et al.. (2010). Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer with Acquired Endocrine Resistance. Clinical Cancer Research. 16(5). 1486–1497. 70 indexed citations

16.

Johnston, Stephen & Carlos L. Arteaga. (2009). Lapatinib (Tykerb) plus letrozole (Femara) or letrozole alone for postmenopausal hormone receptor-positive metastatic breast cancer. 34(2). 1 indexed citations

17.

Martin, Lesley‐Ann, Julia E. Head, Sunil Pancholi, et al.. (2007). The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Molecular Cancer Therapeutics. 6(9). 2458–2467. 37 indexed citations

18.

Johnston, Stephen, Julia E. Head, Sunil Pancholi, et al.. (2003). Integration of Signal Transduction Inhibitors with Endocrine Therapy. Clinical Cancer Research. 9(1). 3 indexed citations

19.

Head, Julia E. & Stephen Johnston. (2003). Protein farnesyltransferase inhibitors. Expert Opinion on Emerging Drugs. 8(1). 163–178. 19 indexed citations

20.

Newby, Jacqueline C., Stephen Johnston, I E Smith, & Mitch Dowsett. (1997). Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.. PubMed. 3(9). 1643–51. 156 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact